Literature DB >> 21668415

Comparison of carbamazepine rash in multiple sclerosis and epilepsy.

M Shirzadi1, S Alvestad, H Hovdal, K Espeset, S Lydersen, E Brodtkorb.   

Abstract

OBJECTIVES: Studies on the comorbidity of multiple sclerosis (MS) and allergic disorders have shown conflicting results. Carbamazepine (CBZ) is widely used in MS to control pain. We have compared the incidence of rash from CBZ use in MS and epilepsy.
MATERIALS AND METHODS: Consecutive adult patients with MS and epilepsy were studied retrospectively. A detailed survey of medical records concerning CBZ treatment was performed.
RESULTS: A total of 495 patients with epilepsy and 442 patients with MS were included. Sixty-five per cent of patients with epilepsy and 20% of patients with MS had used CBZ. In CBZ-exposed patients, rash occurred in 15/89 (17%) in MS and in 43/323 (13%) in epilepsy, a difference which was not significant. Women below 50 years experienced more skin reactions than older women and men. The unadjusted odds ratio (OR) for rash in the MS vs epilepsy group was 1.32 (CI 0.70-2.51, P = 0.40). Adjusting groups for gender and age reduced the OR to 1.11 (CI 0.56-2.19, P = 0.76).
CONCLUSION: Compared with epilepsy, which is only rarely caused by immunological mechanisms, the autoimmune disorder MS was not associated with a different occurrence of CBZ skin reactions. The trend towards an increased occurrence of rashes in MS can partly be explained by a higher predisposition to CBZ rash in women of fertile age.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668415     DOI: 10.1111/j.1600-0404.2011.01553.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Carbamazepine hypersensitivity: progress toward predicting the unpredictable.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

Review 2.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

3.  Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.

Authors:  Taisei Mushiroda; Yukitoshi Takahashi; Teiichi Onuma; Yoshiaki Yamamoto; Tetsumasa Kamei; Tohru Hoshida; Katsuya Takeuchi; Kotaro Otsuka; Mitsutoshi Okazaki; Masako Watanabe; Kosuke Kanemoto; Tomohiro Oshima; Atsushi Watanabe; Shiro Minami; Kayoko Saito; Hisashi Tanii; Yasushi Shimo; Minoru Hara; Shinji Saitoh; Toshihiko Kinoshita; Masaki Kato; Naoto Yamada; Naoki Akamatsu; Toshihiko Fukuchi; Shigenobu Ishida; Shingo Yasumoto; Atsushi Takahashi; Takeshi Ozeki; Takahisa Furuta; Yoshiro Saito; Nobuyuki Izumida; Yoko Kano; Tetsuo Shiohara; Michiaki Kubo
Journal:  JAMA Neurol       Date:  2018-07-01       Impact factor: 18.302

4.  Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis.

Authors:  Israa Alfares; Muhammad Shahid Javaid; Zhibin Chen; Alison Anderson; Ana Antonic-Baker; Patrick Kwan
Journal:  CNS Drugs       Date:  2021-02-12       Impact factor: 5.749

5.  Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Authors:  Georg Anton Giæver Beiske; Trygve Holmøy; Antonie Giæver Beiske; Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Mult Scler Int       Date:  2015-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.